Low-Dose Immunotherapy in Head and Neck Cancer: A Randomized Study

Abstract

To our knowledge, this is the first-ever randomized study to demonstrate that the addition of low-dose nivolumab to metronomic chemotherapy improved OS and is an alternative standard of care for those who cannot access full-dose checkpoint inhibitors.